Matthew Gubens, MD, MS (@UCSFCancer) explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic #NSCLC. 🎥 WATCH: targetedonc.com/view/how-to-… #LungCancer #Immunotherapy #Oncology #CancerTreatment | @MattGubensMD

🔎 FDA News: The #FDA has granted fast track designation to SBE303, an investigational Nectin-4–targeting ADC, for advanced #UrothelialCancer following enfortumab vedotin. Read more: targetedonc.com/view/fda-gra… #BladderCancer #GUOncology #CancerTreatment

Real-world evidence has shed new light on prostate cancer treatment strategies. Alicia Morgans, MD, MPH, @DanaFarber, discusses the real-world ARAAT trial and its key findings. targetedonc.com/authors/alic…

🔬 The ADC sofetabart mipitecan showed efficacy and safety in #OvarianCancer, leading to selection of a phase 3 dose for the FRAmework-01 trial. Read more: targetedonc.com/view/https:/… #GynOnc #Oncology #CancerTreatment #CancerResearch

🔎 FDA News: The #FDA has granted orphan drug designation to onvansertib for R/R #CMML, boosting development of the PLK1 inhibitor after early signals of activity. Read more: targetedonc.com/view/onvanse… #Leukemia #Hematology #Oncology #BloodCancer #CancerTreatment

🚨 Our coverage of #ESMO26 starts tomorrow! Visit hubs.li/Q04BT_HC0 for exclusive interviews and comprehensive coverage of the meeting's top news. 📰

🔬 Discharge doesn’t necessarily mean the end of toxicity management after lifileucel (Amtagvi) TIL therapy for advanced #melanoma. New findings in @JCO_ASCO highlight postdischarge AEs and the importance of continued monitoring. Read more: targetedonc.com/view/lifileu…

Something new is coming into focus. 👀 A fresh look. A new chapter. The same commitment to connecting science with everyday practice. Stay tuned. The reveal is coming soon. 🔜 #ComingSoon #Oncology

🩺 Practice Update: The @NCCN guidelines have incorporated cosibelimab (Unloxcyt) for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. Read more: targetedonc.com/view/nccn-co… #CSCC #SkinCancer #Oncology #CancerCare

Morana Vojnic, MD, MBA (@RutgersCancer) discussed how FET-PET imaging, advanced molecular testing, and personalized treatment approaches are shaping the future of brain tumor care. 💬 Full interview: targetedonc.com/view/vojnic-… #NeuroOncology #PrecisionMedicine | @Moranaaa

🔬 A new analysis reveals major gaps in US #TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities. Read more: targetedonc.com/view/triple-… #RuralHealth #CancerCare #ClinicalTrials #BreastCancer

Alicia Morgans, MD, MPH (@DanaFarber) discusses findings from ARAAT, a real-world analysis comparing darolutamide vs abiraterone when each is added to an ADT and docetaxel backbone in #mHSPC. 🎥 WATCH: targetedonc.com/view/dr-alic… #Oncology #ProstateCancer #RWD | @CaPsurvivorship

🔬 The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with #PolycythemiaVera receiving standard-of-care therapy. Read more: targetedonc.com/view/rusfert… #Hematology #ClinicalResearch

🔎 FDA News: MC001, an investigational chemoimmunotherapy ADC, has received #FDA fast track designation for #PancreaticCancer. Read more: targetedonc.com/view/mc001-r… #Oncology #CancerTreatment #GIOncology

🔬 Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell #RCC, alone and in key first-line combinations. Read more: targetedonc.com/view/casdati… #ccRCC #KidneyCancer #GUOncology #Oncology

📊 According to a new analysis, rural #BreastCancer deaths are rising faster than urban rates, driven by low income, later diagnosis, and treatment gaps. Read more: targetedonc.com/view/rural-u… #CancerCare #HealthDisparities #PublicHealth #Epidemiology

🔬 The TASKIN trial found a 12-month OS rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors. Read more: targetedonc.com/view/vilamak… #ColorectalCancer #CRC #GIOncology #Oncology

What does taletrectinib’s sNDA approval change for patients with ROS1-positive non–small cell lung cancer? On this episode of Targeted Talks, Lyudmila Bazhenova, MD, breaks down the long-term efficacy data. targetedonc.com/viewbazhenov…

🔬 SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery. Read more: targetedonc.com/view/neoadju… #Oncology #RCC #KidneyCancer #GUOncology

📢 BREAKING: The #FDA has approved dostarlimab for MSI-H/dMMR locally advanced #RectalCancer, helping many patients avoid surgery, radiation, and chemo. Read more: targetedonc.com/view/dostarl… #GIOncology #FDANews #Oncology #CancerTreatment #CancerCare